Technical Analysis for MTCR - Metacrine, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Historical MTCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 50 DMA Support | Bullish | 5.67% | |
| MACD Bullish Centerline Cross | Bullish | 5.67% | |
| Stochastic Reached Overbought | Strength | 5.67% | |
| Weak + Overbought | Other | 5.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Upper Bollinger Band Resistance | about 11 hours ago | |
| 2x Volume Pace | about 15 hours ago | |
| Gapped Up (Full) | about 16 hours ago | |
| Rose Above Previous Day's High | about 16 hours ago | |
| Rose Above Upper Bollinger Band | about 16 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Metacrine is a clinical-stage biopharmaceutical company building a differentiated pipeline of therapies to treat liver and gastrointestinal (GI) diseases. The company’s most advanced programs, MET409 and MET642, target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. Both MET409 and MET642 are currently being investigated in clinical trials as potential new treatments for non-alcoholic steatohepatitis (NASH).
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diseases Alcohol Chemical Compounds Gastrointestinal Specialty Drugs Steatohepatitis Hepatitis Gastrointestinal Disease Non Alcoholic Fatty Liver Disease Carboxylic Acids Farnesoid X Receptor Fxr Gi Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diseases Alcohol Chemical Compounds Gastrointestinal Specialty Drugs Steatohepatitis Hepatitis Gastrointestinal Disease Non Alcoholic Fatty Liver Disease Carboxylic Acids Farnesoid X Receptor Fxr Gi Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.19 |
| 52 Week Low | 7.64 |
| Average Volume | 67,205 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 8.80 |
| 20-Day Moving Average | 8.44 |
| 10-Day Moving Average | 8.73 |
| Average True Range | 0.53 |
| ADX | 19.38 |
| +DI | 31.59 |
| -DI | 14.96 |
| Chandelier Exit (Long, 3 ATRs ) | 8.91 |
| Chandelier Exit (Short, 3 ATRs ) | 9.33 |
| Upper Bollinger Band | 9.32 |
| Lower Bollinger Band | 7.56 |
| Percent B (%b) | 1.11 |
| BandWidth | 20.80 |
| MACD Line | 0.07 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.1388 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.19 | ||||
| Resistance 3 (R3) | 10.19 | 9.97 | 10.07 | ||
| Resistance 2 (R2) | 9.97 | 9.80 | 9.97 | 10.03 | |
| Resistance 1 (R1) | 9.74 | 9.69 | 9.63 | 9.74 | 10.00 |
| Pivot Point | 9.52 | 9.52 | 9.47 | 9.52 | 9.52 |
| Support 1 (S1) | 9.29 | 9.35 | 9.18 | 9.29 | 9.02 |
| Support 2 (S2) | 9.07 | 9.24 | 9.07 | 8.99 | |
| Support 3 (S3) | 8.84 | 9.07 | 8.95 | ||
| Support 4 (S4) | 8.84 |
